Upgrade to SI Premium - Free Trial

BMO Capital Reiterates Outperform Rating on Abbvie (ABBV): today's data "reflective of an opportunity to diversify its business beyond the I&I"

March 9, 2026 9:35 AM
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $258.00 price target on Abbvie (NYSE: ABBV)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments